Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2026 07:30 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Participate at Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
February 12, 2026 16:15 ET | Source: NervGen Pharma Corp.

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
February 11, 2026 07:00 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
February 09, 2026 07:00 ET | Source: NervGen Pharma Corp.

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
January 20, 2026 07:00 ET | Source: NervGen Pharma Corp.

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

NervGen Pharma today announced that the Company will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026 in New York City
January 08, 2026 06:30 ET | Source: NervGen Pharma Corp.

NervGen Pharma Begins Trading on Nasdaq Today

NervGen Pharma's common shares have been approved for listing on Nasdaq and will begin trading today, under the symbol "NGEN"